Focus Partners Wealth
CRSP icon

Focus Partners Wealth’s CRISPR Therapeutics CRSP Stock Holding History

Focus Partners Wealth’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$217K Buy
4,560
+293
+7% +$15.5K ﹤0.01% 2380
2025
Q4 		$226K Sell
4,267
-2,327
-35% -$139K ﹤0.01% 2389
2025
Q3 		$444K Buy
6,594
+1,170
+22% +$67.2K ﹤0.01% 1661
2025
Q2 		$264K Buy
+5,424
New +$210K ﹤0.01% 1746
2025
Q1 		– Sell
-6,082
Closed -$239K – 1933
2024
Q4 		$239K Buy
+6,082
New +$287K ﹤0.01% 1654
2024
Q3 		– Sell
-3,973
Closed -$215K – 1597
2024
Q2 		$215K Buy
+3,973
New +$230K ﹤0.01% 1146

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Focus Partners Wealth's CRSP Position: Q1 2026 in Review

Focus Partners Wealth increased its CRISPR Therapeutics (CRSP) stake by 6.9% in Q1 2026, buying an estimated $15.5K and bringing the position to 4,560 shares worth $217K. The position accounts for ﹤0.01% of the portfolio, ranked #2380.

Focus Partners Wealth first reported a position in CRSP in Q2 2024 and has held it in 6 quarters since. The position peaked at $444K in Q3 2025. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Focus Partners Wealth held 4,560 shares of CRISPR Therapeutics worth $217K as of Q1 2026.
  • Focus Partners Wealth bought 293 CRISPR Therapeutics shares in Q1 2026, an estimated $15.5K.
  • CRISPR Therapeutics made up ﹤0.01% of Focus Partners Wealth's portfolio in Q1 2026, its #2380 holding.
  • Focus Partners Wealth first reported a position in CRISPR Therapeutics in Q2 2024 and has held it in 6 quarters since.
  • Focus Partners Wealth's CRISPR Therapeutics position peaked at $444K in Q3 2025.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Focus Partners Wealth's 13F filing for Q1 2026, filed 15 May 2026.